Diane R. Mould

6.0k total citations · 1 hit paper
140 papers, 4.5k citations indexed

About

Diane R. Mould is a scholar working on Immunology, Genetics and Oncology. According to data from OpenAlex, Diane R. Mould has authored 140 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Immunology, 33 papers in Genetics and 31 papers in Oncology. Recurrent topics in Diane R. Mould's work include Inflammatory Bowel Disease (31 papers), Chronic Lymphocytic Leukemia Research (24 papers) and Microscopic Colitis (24 papers). Diane R. Mould is often cited by papers focused on Inflammatory Bowel Disease (31 papers), Chronic Lymphocytic Leukemia Research (24 papers) and Microscopic Colitis (24 papers). Diane R. Mould collaborates with scholars based in United States, United Kingdom and Canada. Diane R. Mould's co-authors include Shaun D. Black, William J. Sandborn, Íngrid Ordás, B G Feagan, Bruce Green, Kevin Sweeney, Marla C. Dubinsky, Keith Nieforth, Bernd Meibohm and Richard N. Upton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Diane R. Mould

136 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

2016 292 citations Diane R. Mould et al. CPT Pharmacometrics & Systems Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diane R. Mould United States	34	1.3k	1.2k	1.1k	923	686	140	4.5k
Gilles Paintaud France	43	1.7k 1.3×	1.7k 1.4×	1.5k 1.3×	948 1.0×	1.4k 2.1×	194	6.3k
Xiaowei Liu China	38	571 0.4×	1.2k 0.9×	581 0.5×	2.2k 2.4×	376 0.5×	255	6.3k
Paul E. Klotman United States	56	806 0.6×	1.1k 0.9×	1.1k 1.0×	2.7k 2.9×	134 0.2×	196	9.7k
Péter Fritz Germany	39	966 0.7×	694 0.6×	440 0.4×	1.8k 1.9×	509 0.7×	133	6.4k
Henrik Grönberg Sweden	57	2.0k 1.5×	950 0.8×	697 0.6×	3.2k 3.4×	487 0.7×	263	11.6k
Hong Zhang China	40	341 0.3×	1.2k 1.0×	1.1k 1.0×	1.1k 1.2×	172 0.3×	213	6.0k
Pingfu Fu United States	50	402 0.3×	826 0.7×	749 0.7×	2.4k 2.6×	1.4k 2.0×	319	8.2k
Thomas Rutherford United States	46	623 0.5×	1.2k 1.0×	636 0.6×	2.9k 3.2×	335 0.5×	195	7.9k
Wei Chen China	47	415 0.3×	1.1k 0.9×	639 0.6×	3.6k 3.9×	540 0.8×	272	8.2k
Kevin Horgan United States	34	812 0.6×	2.3k 1.9×	541 0.5×	1.0k 1.1×	820 1.2×	63	9.1k

Countries citing papers authored by Diane R. Mould

Since Specialization

Citations

This map shows the geographic impact of Diane R. Mould's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diane R. Mould with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diane R. Mould more than expected).

Fields of papers citing papers by Diane R. Mould

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diane R. Mould. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diane R. Mould. The network helps show where Diane R. Mould may publish in the future.

Co-authorship network of co-authors of Diane R. Mould

This figure shows the co-authorship network connecting the top 25 collaborators of Diane R. Mould. A scholar is included among the top collaborators of Diane R. Mould based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diane R. Mould. Diane R. Mould is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stein, Ronen, Dan Turner, Séamus Hussey, et al.. (2025). Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study. Alimentary Pharmacology & Therapeutics. 61(6). 1000–1010. 1 indexed citations

Fitch, Richard M., et al.. (2025). Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium (XP‐8121). Clinical and Translational Science. 18(5). e70244–e70244. 1 indexed citations

Mould, Diane R., et al.. (2024). Inflammation‐mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology. 90(11). 2811–2822. 2 indexed citations

Terranova, Nadia, Diane R. Mould, Yulia Vugmeyster, et al.. (2023). Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials. CPT Pharmacometrics & Systems Pharmacology. 13(1). 143–153. 4 indexed citations

Gibson, Peter R., et al.. (2023). Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis. The Journal of Clinical Pharmacology. 64(4). 399–409. 2 indexed citations

Primas, Christian, Walter Reinisch, John C. Panetta, et al.. (2022). Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. Journal of Clinical Medicine. 11(12). 3316–3316. 10 indexed citations

Mould, Diane R., et al.. (2022). CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19. Pharmacy & Pharmacology. 10(5). 460–471.

Wang, Yow‐Ming, et al.. (2018). Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?. The AAPS Journal. 20(6). 99–99. 24 indexed citations

Reinisch, Walter, et al.. (2018). P401 Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodies. Journal of Crohn s and Colitis. 12(supplement_1). S307–S308. 4 indexed citations

10.

Chan, Phyllis, et al.. (2016). Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations. Clinical Pharmacokinetics. 55(12). 1559–1572. 2 indexed citations

11.

Mould, Diane R. & Marla C. Dubinsky. (2015). Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. The Journal of Clinical Pharmacology. 55(S3). S51–9. 40 indexed citations

12.

Casteele, Niels Vande, Diane R. Mould, Ann Gils, et al.. (2015). Tu1308 Adequate Trough Concentrations and Sustained TNF Suppression Early on During Induction Therapy With Adalimumab Predict Remission in Anti-TNF Naïve Crohn's Disease Patients. Gastroenterology. 148(4). S–854. 2 indexed citations

13.

Dotan, Iris, Yulia Ron, Henit Yanai, et al.. (2014). Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 20(12). 2247–2259. 224 indexed citations

14.

Ghosh, Subrata, Benjamin Pariente, Diane R. Mould, et al.. (2014). New tools and approaches for improved management of inflammatory bowel diseases. Journal of Crohn s and Colitis. 8(10). 1246–1253. 9 indexed citations

15.

Ji, Jia, Diane R. Mould, Kristie A. Blum, et al.. (2013). A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol. Clinical Cancer Research. 19(5). 1269–1280. 19 indexed citations

16.

O’Connor, Owen A., Steven M. Horwitz, Paul A. Hamlin, et al.. (2009). Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. Journal of Clinical Oncology. 27(26). 4357–4364. 131 indexed citations

17.

Gibbs, Megan, et al.. (2009). Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder. Journal of Pharmacokinetics and Pharmacodynamics. 36(1). 63–80. 17 indexed citations

18.

Mould, Diane R., Andreas Baumann, Jens Kuhlmann, et al.. (2007). Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath^®) in patients with chronic lymphocytic leukaemia and its link to treatment response. British Journal of Clinical Pharmacology. 64(3). 278–291. 92 indexed citations

19.

Mould, Diane R., Gini F. Fleming, Kathleen M. Darcy, & David R. Spriggs. (2006). Population analysis of a 24‐h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. British Journal of Clinical Pharmacology. 62(1). 56–70. 18 indexed citations

20.

Black, Shaun D. & Diane R. Mould. (1991). Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications. Analytical Biochemistry. 193(1). 72–82. 299 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact